Evidence map›Paper›PMID 32536688›Full record

ArticleMolecular psychiatry2021

Insulin receptor substrate in brain-enriched exosomes in subjects with major depression: on the path of creation of biosignatures of central insulin resistance.

Carla Nasca, Josh Dobbin, Benedetta Bigio, Kathleen Watson, Paolo de Angelis, Marin Kautz, Ashly Cochran, Aleksander A Mathé, James H Kocsis, Francis S Lee and 3 more

Open access · greenAbstract read
In one paragraph

Article in Molecular psychiatry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 109 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Transcriptomics and psychotherapy: An integrative review.Brain, behavior, & immunity - health · 2024
    Review

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Carla NascaHarold and Margaret Milliken Hatch Laboratory of Neuroendocrinology, The Rockefeller University, New York, NY, USA. cnasca@rockefeller.edu.ORCID http://orcid.org/0000-0003-3348-6783
Josh DobbinHarold and Margaret Milliken Hatch Laboratory of Neuroendocrinology, The Rockefeller University, New York, NY, USA.
Benedetta BigioHarold and Margaret Milliken Hatch Laboratory of Neuroendocrinology, The Rockefeller University, New York, NY, USA.
Kathleen WatsonCenter for Neuroscience in Women's Health, Stanford University, Palo Alto, CA, 91304, USA.
Paolo de AngelisHarold and Margaret Milliken Hatch Laboratory of Neuroendocrinology, The Rockefeller University, New York, NY, USA.ORCID http://orcid.org/0000-0003-4731-2979
Marin KautzDepartment of Psychiatry, Mood and Anxiety Disorders Program, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Ashly CochranDepartment of Psychiatry, Weill Cornell Medical College, New York, NY, USA.
Aleksander A MathéDepartment of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
James H KocsisDepartment of Psychiatry, Weill Cornell Medical College, New York, NY, USA.
Francis S LeeDepartment of Psychiatry, Weill Cornell Medical College, New York, NY, USA.
James W MurroughDepartment of Psychiatry, Mood and Anxiety Disorders Program, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Bruce S McEwenHarold and Margaret Milliken Hatch Laboratory of Neuroendocrinology, The Rockefeller University, New York, NY, USA.
Natalie RasgonHarold and Margaret Milliken Hatch Laboratory of Neuroendocrinology, The Rockefeller University, New York, NY, USA. nrasgon@stanford.edu.ORCID http://orcid.org/0000-0002-2894-2353
Rockefeller University · USCornell University · USIcahn School of Medicine at Mount Sinai · USKarolinska Institutet · SEStanford University · US

Funding

Pioglitazone for Treatment of Unremitted Depression in Insulin Resistant PatientsR21MH093948 · NIMH · STANFORD UNIVERSITY · PI RASGON, NATALIE L · 2011 to 2012
$435k
NIMH NIH HHS R21 MH093948
6 · The paper itself

Abstract

Insulin signaling is critical for neuroplasticity, cerebral metabolism as well as for systemic energy metabolism. In rodent studies, impaired brain insulin signaling with resultant insulin resistance (IR) modulates synaptic plasticity and the corresponding behavioral functions. Despite discoveries of central actions of insulin, in vivo molecular mechanisms of brain IR until recently have proven difficult to study in the human brain. In the current study, we leveraged recent technological advances in molecular biology and herein report an increased number of exosomes enriched for L1CAM, a marker predominantly expressed in the brain, in subjects with major depressive disorder (MDD) as compared with age- and sex-matched healthy controls (HC). We also report increased concentration of the insulin receptor substrate-1 (IRS-1) in L1CAM

Indexed as

ExosomesInsulin ResistanceMajor Depressive DisorderBrainDepressionFemaleHumansInsulinMalePhosphoproteinsPhosphorylationReceptor, InsulinInsulinPhosphoproteinsReceptor, Insulin

Identifiers

PMID32536688
PMCPMC7787430
OpenAlexW3034937256

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.